|
Name |
Palmarumycin C12
|
| Molecular Formula | C20H14O6 | |
| IUPAC Name* |
(1'aS,7'S,7'aS)-spiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene-3,2'-7,7a-dihydro-1aH-naphtho[2,3-b]oxirene]-3',6',7'-triol
|
|
| SMILES |
C1=CC2=C3C(=C1)OC4([C@@H]5[C@@H](O5)[C@H](C6=C(C=CC(=C64)O)O)O)OC3=CC=C2
|
|
| InChI |
InChI=1S/C20H14O6/c21-10-7-8-11(22)16-15(10)17(23)18-19(24-18)20(16)25-12-5-1-3-9-4-2-6-13(26-20)14(9)12/h1-8,17-19,21-23H/t17-,18-,19-/m0/s1
|
|
| InChIKey |
YUSPOKSZSCPJJV-FHWLQOOXSA-N
|
|
| Synonyms |
Palmarumycin C12; (1'As,7'S,7'aS)-spiro[2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene-3,2'-7,7a-dihydro-1aH-naphtho[2,3-b]oxirene]-3',6',7'-triol; (2'S,3'S,4'S)-2',3'-Epoxy-2',3'-dihydrospiro[naphtho[1,8-de]-1,3-dioxin-2,1'(4'H)-naphthalene]-4',5',8'-triol
|
|
| CAS | NA | |
| PubChem CID | 10360496 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 350.3 | ALogp: | 2.3 |
| HBD: | 3 | HBA: | 6 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 91.7 | Aromatic Rings: | 6 |
| Heavy Atoms: | 26 | QED Weighted: | 0.425 |
| Caco-2 Permeability: | -5.187 | MDCK Permeability: | 0.00003420 |
| Pgp-inhibitor: | 0.01 | Pgp-substrate: | 0.005 |
| Human Intestinal Absorption (HIA): | 0.035 | 20% Bioavailability (F20%): | 0.016 |
| 30% Bioavailability (F30%): | 0.155 |
| Blood-Brain-Barrier Penetration (BBB): | 0.05 | Plasma Protein Binding (PPB): | 97.54% |
| Volume Distribution (VD): | 0.516 | Fu: | 2.31% |
| CYP1A2-inhibitor: | 0.165 | CYP1A2-substrate: | 0.105 |
| CYP2C19-inhibitor: | 0.21 | CYP2C19-substrate: | 0.109 |
| CYP2C9-inhibitor: | 0.815 | CYP2C9-substrate: | 0.901 |
| CYP2D6-inhibitor: | 0.788 | CYP2D6-substrate: | 0.181 |
| CYP3A4-inhibitor: | 0.572 | CYP3A4-substrate: | 0.229 |
| Clearance (CL): | 7.716 | Half-life (T1/2): | 0.603 |
| hERG Blockers: | 0.012 | Human Hepatotoxicity (H-HT): | 0.199 |
| Drug-inuced Liver Injury (DILI): | 0.909 | AMES Toxicity: | 0.953 |
| Rat Oral Acute Toxicity: | 0.896 | Maximum Recommended Daily Dose: | 0.097 |
| Skin Sensitization: | 0.941 | Carcinogencity: | 0.89 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.882 |
| Respiratory Toxicity: | 0.9 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC003746 | ![]() |
0.762 | D06TJJ | ![]() |
0.301 | ||
| ENC002639 | ![]() |
0.682 | D0AZ8C | ![]() |
0.281 | ||
| ENC005549 | ![]() |
0.670 | D0Q5UQ | ![]() |
0.250 | ||
| ENC005722 | ![]() |
0.670 | D0H6QU | ![]() |
0.245 | ||
| ENC002038 | ![]() |
0.656 | D04AIT | ![]() |
0.243 | ||
| ENC005548 | ![]() |
0.582 | D02FCQ | ![]() |
0.241 | ||
| ENC002530 | ![]() |
0.564 | D08CCE | ![]() |
0.239 | ||
| ENC003202 | ![]() |
0.529 | D02TJS | ![]() |
0.237 | ||
| ENC003200 | ![]() |
0.529 | D0J7RK | ![]() |
0.234 | ||
| ENC001112 | ![]() |
0.526 | D06ZEE | ![]() |
0.231 | ||